X4’s chief executive Paula Ragan said the company will work closely with the FDA during the review “with the goal of bringing mavorixafor to people with WHIM syndrome as quickly as possible.” ...

Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist ...